Efficacy and clinical safety of ramelteon: An evidence-based review

Sleep Medicine Reviews

Volumn 12, Issue 4, 2008, Pages 319-332

  Sateia, Michael J ^a   Kirby Long, Paula ^a   Taylor, Jennifer L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Insomnia; Melatonin; Ramelteon; Rozerem

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIPROFLOXACIN; DEXTROMETHORPHAN; DIAZEPAM; DONEPEZIL; ENOXACIN; FLUCONAZOLE; FLUMAZENIL; FLUVOXAMINE; KETOCONAZOLE; MELATONIN; MEXILETINE; MIDAZOLAM; MORPHINE; NORFLOXACIN; OMEPRAZOLE; PENTOBARBITAL; PLACEBO; RAMELTEON; RIFAMPICIN; TACRINE; THEOPHYLLINE; TRIAZOLAM; WARFARIN; ZOLPIDEM;

BEDTIME DOSAGE; BINDING AFFINITY; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EVENING DOSAGE; FIRST PASS EFFECT; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSOMNIA; JET LAG; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; POLYSOMNOGRAPHY; PROLACTIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SLEEP DISORDER; SLEEP STAGE; SLEEP TIME; SOMNOLENCE; SORE THROAT; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANIMALS; ATTENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; LONG-TERM CARE; METABOLIC CLEARANCE RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; WAKEFULNESS;

EID: 46049106523     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2007.12.005     Document Type: Review

References (48)

1. Uchikawa O., Fukatsu K., Tokunoh R., et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 45 19 (2002) 4222-4239
2. Miyamoto M., Nishikawa H., Doken Y., Hirai K., Uchikawa O., and Ohkawa S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 27 7 (2004) 1319-1325
3. Kato K., Hirai K., Nishiyama K., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48 2 (2005) 301-310
4. Liu C., Weaver D.R., Jin X., et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19 1 (1997) 91-102
5. Dubocovich M.L., Yun K., Al-Ghoul W.M., Benloucif S., and Masana M.I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 12 12 (1998) 1211-1220
6. Wang F., Li J., Wu C., Yang J., Xu F., and Zhao Q. The GABA(A) receptor mediates the hypnotic activity of melatonin in rats. Pharmacol Biochem Behav 74 3 (2003) 573-578
7. Buscemi N., Vandermeer B., Hooton N., et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20 12 (2005) 1151-1158
8. Buscemi N., Vandermeer B., Hooton N., et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332 7538 (2006) 385-393
9. Brzezinski A., Vangel M.G., Wurtman R.J., et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9 1 (2005) 41-50
10. Herxheimer A., and Petrie K.J. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2 (2002) CD001520
11. **The most important references are denoted by an asterisk. Karim A., Tolbert D., and Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 46 2 (2006) 140-148
12. Greenblatt D.J., Harmatz J.S., and Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 47 4 (2007) 485-496
13. Stevenson S., Bryson S., Amakye D., et al. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin Pharmacol Ther (Abstract) 75 2 (2004) P22
14. Yukuhiro N., Kimura H., Nishikawa H., Ohkawa S., Yoshikubo S., and Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 1027 1/2 (2004) 59-66
15. Hirai K., Kita M., Ohta H., et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 20 1 (2005) 27-37
16. *. Roth T., Stubbs C., and Walsh J.K. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28 3 (2005) 303-307
17. Zammitt G., Schwartz H., Wang-Wiegand S., Zhang J., and Roth T. Effect of ramelteon, a selective MT1/MT2 receptor agonist, in a first-night-effect model of transient insomnia. Sleep 29 Abstract Suppl. (2006) A238
18. *. Erman M., Seiden D., Zammit G., Sainati S., and Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 7 1 (2006) 17-24
19. Zammit G., Roth T., Erman M., Sainati S., Weigand S., and Zhang J. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 28 Abstract Suppl. (2005) A228-A229
20. Mini L., Wang-Weigand S., and Zhang J. Effects of ramelteon 8 mg on latency to persistent sleep in adults with severe sleep-initiation difficulty: post-hoc analysis of a 5-week trial. Sleep 30 Abstract Suppl. (2007) A243
21. Mini L., Maloney P., Wang-Weigand S., Zhang J., and Kasten K. Efficacy and next-day residual effects of ramelteon 8 mg in adults with chronic insomnia: a combined analysis of 2 double-blind, placebo-controlled, crossover trials. Sleep 30 Abstract Suppl. (2007) A229-A230
22. *. DeMicco M., Wang-Weigand S., and Zhang J. Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a one-year study. Sleep 29 Abstract Suppl. (2006) A234
23. Roth T., Seiden D., Sainati S., Wang-Weigand S., Zhang J., and Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7 4 (2006) 312-318
24. *. Roth T., Seiden D., Wang-Weigand S., and Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23 5 (2007) 1005-1014
25. Mini L.J., Wang-Weigand S., Zhang J., and Kasten K. Self-reported efficacy of 8 mg ramelteon in elderly chronic insomnia patients with severe sleep-initiation difficulty. Sleep 29 Abstract Suppl. (2006) A237
26. Nishida N.S.M., Wakasa Y., Awasaki Y., Yamamoto M., and Yanagita T. reinforcing effect of ramelteon assessed by intravenous self-administration experiments in rhesus monkeys. Sleep 28 Abstract Suppl. (2005) A45
27. France C.W.R., and Cruz C. Lack of primary physical dependence of ramelteon in rhesus monkeys. Sleep 28 Abstract Suppl. (2005) A45
28. France C.W.R., Cruz C., and McMahon L. Ramelteon does not have benzodiazepine agonist-like discriminative stimulus effects in normal or diazepam-dependent rhesus monkeys. Sleep 28 Abstract Suppl. (2005) A45
29. *. Johnson M.W., Suess P.E., and Griffiths R.R. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 63 10 (2006) 1149-1157
30. McGechan A., and Wellington K. Ramelteon. CNS Drugs 19 12 (2005) 1057-1065
31. *. Laustsen G., and Andersen M. Ramelteon (rozerem): a novel approach for insomnia treatment. Nurse Pract 31 4 (2006) 52-55
32. Dolder C., Nelson M., and McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?. CNS Drugs 21 5 (2007) 389-405
33. Karim A.T.D., Cao C., Munsaka M., and Copa A. Study to assess the steady-state drug-drug interaction of omeprazole with ramelteon in healthy adults. Sleep 28 Abstract Suppl. (2005) A46
34. Karim A.B.D., Siebert F., and Zhao Z. Pharmacokinetic effect of multiple oral doses of donepezil on ramelteon, and vice versa, in healthy adults. Sleep 30 Abstract Suppl. (2007) A244
35. Tolbert D.K.A., Johnson J., Cao C., Zhao Z., and Sainati S.M. Two-period crossover study to assess the drug interaction between ramelteon (TAK-375) and theophylline in healthy adults. Sleep 27 Abstract Suppl. (2004) A48
36. Karim A.T.D., Cao C., Zhao Z., and Harris S. Open-label assessment of the pharmacokinetics and pharmacodynamics of warfarin in the presence of multiple doses of ramelteon in healthy adults. Sleep 28 Abstract Suppl. (2005) A45-A46
37. Tolbert D.K.A., Cao C., Johnson J., and Sainati S.M. Study to assess drug interaction between ramelteon (TAK-375) and dextromethorphan in healthy adults. Sleep 27 Abstract Suppl. (2004) A50
38. Miyamoto M. Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett 402 3 (2006) 201-204
39. Wang-Weigand S.Z.G., and Peng X. Effect of ramelteon on middle-of-the-night balance, mobility, and memory performance in older adults. Sleep 30 Abstract Suppl. (2007) A244
40. Seiden D., Zee P., Weigand S., Sainati S., Bayuk J., Zhang J., et al. Double-blind, placebo-controlled outpatient clinical trial of ramelteon for the treatment of chronic insomnia. Sleep 28 Abstract Suppl. (2005) A228
41. *. Zammit G., Erman M., Wang-Weigand S., Sainati S., Zhang J., and Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 3 5 (2007) 495-504
42. *. Kryger M., Wang-Weigand S., and Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath 11 3 (2007) 159-164
43. *. Richardson G.W.-W.S., Zhang J., and DeMicco M. Long-term safety of ramelteon Treatment in adults with chronic insomnia: a 1-year study. Sleep 29 Abstract Suppl. (2006) A233
44. Richardson G.W.-W.S., Sainati S., and Dermissie S. A double-blind placebo controlled phase III study of the long-term effects of ramelteon on endocrine function in adults with chronic insomnia. Sleep 29 Abstract Suppl. (2006) A232
45. Smith M.T., Perlis M.L., Park A., et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 159 1 (2002) 5-11
46. Krystal A.D., Walsh J.K., Laska E., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26 7 (2003) 793-799
47. Nowell P.D., Mazumdar S., Buysse D.J., Dew M.A., Reynolds III C.F., and Kupfer D.J. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 278 24 (1997) 2170-2177
48. Seiden D, Wang-Weigand S, Zhang J, et al. Sleep promoting effects of ramelteon, a selective MT1/MT2 receptor agonist, in older adults with chronic insomnia. Sleep 2006, 29 (Abstract supplement): A238.